PIC/S Advises On Safe On-Site Inspections During COVID-19 Pandemic
The international association of pharmaceutical inspectorates, PIC/S, has developed a structured process that national inspectors can use to assess their risk of exposure to COVID-19 when carrying out routine on-site inspections.
You may also be interested in...
The MHRA intends to drop around 300 roles as it faces a financial crunch after leaving the EU and other pressures.
The Association of Contract Research Organizations’ revised toolkit on decentralized trials explains how to deal with data quality and integrity.
The European Medicines Agency has updated its reflection paper on methodologies for comparative quality assessment. The paper clarifies expectations on the assessment of similarity for manufacturing changes and for generic and biosimilar development by introducing the concept of “similarity condition.”